Skip to main content
main-content

09-13-2017 | Exenatide | EASD 2017 | News

News in brief

DURATION-8: Exenatide efficacy durable to 1 year

medwireNews: The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.

Around three-quarters of the original 695 participants completed 52 weeks of follow-up, at which point their glycated hemoglobin levels were 1.75% below baseline in those given dual therapy, compared with 1.38% and 1.23% below baseline in patients randomly assigned to monotherapy with exenatide and dapagliflozin, respectively. These levels represented a slight deterioration from the respective 1.98%, 1.60%, and 1.39% reductions recorded at the 28-week follow-up, but were still significantly better than at baseline.

At 52 weeks, 33.8% of patients given dual treatment had HbA1c levels below 7.0%, as did 24.2% and 15.2% of those given exenatide and dapagliflozin, respectively, reported Cristian Guja (“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania) at the EASD annual meeting in Lisbon, Portugal.

In addition, he said that patients’ 28-week improvements in fasting plasma glucose, 2-hour post-prandial glucose, bodyweight, and blood pressure were sustained at the 1-year follow-up. There were no unexpected safety findings, and the overall rates of hypoglycemia were very low.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

Related topics